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Stephan Wenninger*, Federica Montagnese and Benedikt Schoser
Friedrich-Baur-Institute, Klinikum der Universität München, Munich, Germany
Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multi-
systemic muscular dystrophies in adulthood. They are progressive, autosomal dominant 
diseases caused by an abnormal expansion of an unstable nucleotide repeat located 
in the non-coding region of their respective genes DMPK for DM1 and CNBP in DM2. 
Clinically, these multisystemic disorders are characterized by a high variability of mus cular 
and extramuscular symptoms, often causing a delay in diagnosis. For both subtypes, 
many symptoms overlap, but some differences allow their clinical distinction. This article 
highlights the clinical core features of myotonic dystrophies, thus facilitating their early 
recognition and diagnosis. Particular attention will be given to signs and symptoms of 
muscular involvement, to issues related to respiratory impairment, and to the multiorgan 
involvement. This article is part of a Special Issue entitled “Beyond Borders: Myotonic 
Dystrophies—A European Perception.”
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iNTRODUCTiON
The genetic background of myotonic dystrophies type 1 and 2 (DM1 and DM2) is due to repeat 
expansions of unstable nucleotides in untranslated DNA regions causing mis-splicing of mRNAs, 
which affects almost all cells and organs of the human body. This sum of alterations leads to an 
extremely heterogeneous phenotype with musltisystemic involvement. Many findings and symp-
toms of DM1 and DM2 overlap, but important differences usually allow their prompt clinical 
distinction (Table 2). Both types of myotonic dystrophies represent the most common inherited 
muscle disorders in adulthood with regional variations in prevalence and incidence. In general, 
DM1 occurs more frequently than DM2, with some exeptions in northern and mid European 
countries such as Finland, Germany, and Czech Republic, where DM1 and DM2 are almost equally 
represented. Table 1 provides a useful summary of the country-specific prevalences (1–4).
KeY ASPeCTS iN MYOTONiC DYSTROPHY TYPe 1
For DM1, there is a rough correlation between the expansion of CTG-repeats and the onset of sym-
ptoms as well as the severity of the disease; nevertheless predictions about the clinical features and 
the progression of the disease based on CTG-repeat size should be made very carefully (23, 24). 5 to 
37 CTG-repeats are physiologic in healthy individuals. An expansion between 38 and 49 repeats does 
typically not cause any symptoms and reflects the premutation phenotype (3). The following four 
phenotypes are based on CTG-repeat sizes and onset of symtoms. It is important that phenotypes 
and CTG-repeat sizes do not show a linear and strict relationship and thus may overlap (25, 26):
• a mild phenotype with an expansion of 50–150 CTG-repeats,
• a classic phenotype with a wide span from mild to severe symptoms and an expansion of 50–1,000 
CTG-repeats,
• a childhood/juvenile phenotype with early-onset and typically >800 CTG-repeats, and
• the most severe “congenital form” with usually >1,000 CTG-repeats.
TABLe 2 | Core Clinical Symptoms helpful for differentiating DM1 and DM2.
DM1 DM2
Age of onset Depends on CTG-repeat-size, in common first symptoms earlier than in DM2 30–40
Family history Increasing severity of symptoms throughout generations (anticipation) Variability in symptoms, but 
no evidence for anticipation
General appearance Head Forehead balding
Face Myopathic face, temporal wasting, ptosis
Bulbar Frequent: nasal/slurred speech, dysphagia In some cases: dysphagia
Muscle Weakness Distal Proximal and axial
Myotonia Handgrip, tongue mild proximal
Atrophy Distal, early Proximal, late
Myalgia Not typical, but may be secondary due to regional muscle imbalance Predominant
Sleep disturbances Central sleep apnea, obstructive sleep apnea, respiratory muscle weakness Central sleep apnea
Central nervous system Daytime sleepiness In almost every patient Frequent
Concentration problems Frequent In some patients
Hearing impaiment Rare in adults, more frequent in congenital DM Frequent
Diagnostics Electromyography Myotonic discharges in clinically affected and not affected muscles Proximal, but can be absent
TABLe 1 | Country-specific prevalences of DM1 and DM2.
Country Disease Prevalence (×105) Reference
Croatia DMs 18.1 (5)
Czech Republic DM2 DM2 > DM1 (6)
Finland DM2 10 (7)
Finland DM2 54 (8)
Germany DM2 DM1 = DM2 (9)
Israel DM1 15.7 (10)
Italy DMs 2.1 (11)
Italy DM1 9.3 (12)
Italy DM2 0.9–1 (13)
Italy DM1 9.6–11.7 (13)
Japan DMs 9.1 (14)
Spain, Mallorca DMs 10.8 (15)
New Zeland, Otago DMs 11.6 (16)
North Ireland DMs 11.9 (17)
North Ireland DMs 34 (18)
North UK DM1 10.4 (19)
Quebec DM1 210 (20)
Serbia, Belgrade DM1 5.3 (21)
Taiwan DM1 0.5 (22)
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CTG-repeats will expand in every following generation, and 
fully penetrant alleles occur with >50 CTG-repeats. This results 
in the so called anticipation, a clinical term describing an earlier 
onset with a more severe phenotype in the next generations (26). 
Furthermore, the repeat instability leads notably to premature 
aging of almost all organs, so DM1 may be counted among the 
progeroid diseases (27). The most typical appearance of DM1 is 
the “adult-onset” or “classic” phenotype with a CTG-repeat size 
ranging from 50 to <1,000. It is characterized by a distinctive 
combination of muscular symptoms, such as facial weakness, 
ptosis, grip myotonia, and distal muscle weakness with muscu-
lar atrophy. The classic phenotype is typically accompanied by 
extramuscular symptoms like cognitive impairment, cataracts, 
and diabetes mellitus. Nevertheless, as this multisystem disorder 
often presents with a high variability, some patients may prima-
rily show only non-specific extramuscular symptoms like fatigue, 
daytime sleepiness, gastrointestinal symptoms, or cardiac condu-
ction defects in an early stage of the disease, which could delay 
the diagnosis. Mildly affected patients with CTG-repeat sizes 
50–100 may have normal or only minimally shortened lifespan 
(28). Because of comorbidities, such as cardiac and pulmonary 
complications, life expectancy is, however, reduced in about 70% 
of the patients with the classic phenotype (25).
SPeCiAL ASPeCTS iN MYOTONiC 
DYSTROPHY TYPe 2
DM2 (also referred to as proximal myotonic myopathy) is caused 
by the expansion of the tetranucleotide CCTG-repeat in the first 
intron of CNBP (cellular nucleic acid-binding protein), formerly 
known as zinc finger protein 9 (ZNF9) gene (29). Similar to DM1, 
these expansions are extremely unstable, causing widespread cel-
lular abnormalities of mRNA splicing. In DM2, the expansion 
ranges from 75 to 11,000 with a mean of 5,000 CCTG-repeats. 
In contrast to DM1, there is no correlation between clinical phe-
notype and CCTG-repeat length and no anticipation has been 
observed (29, 30).
MUSCULAR SYMPTOMS
Muscular weakness
The symptoms myotonia, muscular weakness, and muscular 
atrophy are the principal traits of DMs and gave the eponym for 
these two types of the disease. In DM1, patients present with char-
acteristic distally predominant muscular atrophy and weakness 
mainly involving finger flexors, wrist flexors, and foot extensors 
(Figures 1A,B). The latter will cause foot drop and gait disturbance 
with repeated falls and injuries (31). In contrast to this, muscle weak-
ness in DM2 is typically proximal and axial, affecting more consist-
ently the neck flexors, hip flexors, and hip extensors (Figure 1C) 
(30, 32). This predominantly proximal muscular involvement 
has been documented also by MRI studies that showed an early 
degeneration of the erector spinae and gluteus maximus muscles 
(33, 34). Muscle weakness is one of the most frequently reported 
symptoms in DM1 (>45% of patients with adult phenotype) and 
FiGURe 1 | (A,B) Typical distal muscular atrophy in patients with DM1. (C) Atrophy of proximal muscles in a patient with DM2. (D) Figure illustrating the core 
phneotypes of DM1 (left) and DM2 (right). Regions of muscular involvement (weakness and atrophy) are highlighted in red.
FiGURe 2 | The characteristic face of a patient with DM1: long face, 
temporomandibular wasting, balding forehead.
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DM2 (40–55% of patients) (26, 32). Figure 1D illustrates the pre-
dominantly affected muscle groups of patients with DM1 and DM2 
(see Table 2 for differentiating DM1 and DM2).
The typical facial appearance of DM1 patients (“myopathic 
face”—“hatchet face”) is a prominent and early feature and is 
caused by weakness and atrophy of facial muscles and ptosis that 
might give the false impression of a tired, sad, or emotionless 
patient (35). Balding of the forehead and atrophying of the tem-
poral muscle are often seen (Figure 2) and completes the overall 
picture of a patient with DM1. Severe weakness of orbicula ri 
oculi muscles cause not only ptosis but also insufficient eyelid 
closure with risk of recurrent conjunctivitis. This facial muscle 
involvement is usually not seen in DM2 patients, thus it may help 
in differentiating DM1 from DM2 patients (Table 2).
Especially in patients with DM1, the speech can be nasal and 
slurred, due to the weakness of oropharyngeal muscles, some-
times causing chewing and swallowing difficulties.
Myotonia
Myotonia is a more frequent symptom in DM1 mainly affecting 
the fingers (grip myotonia), the jaw, and the tongue (36). Clini-
cally, a warm-up phenomenon is usually observed when myoto-
nia improves with repeated contractions, which is mostly true 
for grip myotonia, but also for myotonia of the tongue and the 
jaw (37, 38). An increased excitability of muscle fibers is thought 
to be the cause for myotonia, leading to continuous discharges 
of repetitive action potentials after voluntary contraction or 
mechanical stimulation (39) in electromyography (EMG). These 
myotonic runs can be detected with EMG even in clinically 
unaffected muscles of DM1 patients, but can be rare or even be 
absent in DM2 (40). On a molecular basis, it has been suggested 
that myotonia is caused by mis-splicing of the chloride channel 
(CLCN1, ClC-1) due to misregulated MBNL1 and CUGBP1 
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(41). Recent studies have investigated the relationship between 
a central nervous system involvement and myotonia, suggest-
ing that myotonia should no longer be considered as a solitary 
peripherally triggered muscular symptom (42, 43). In one fMRI 
study, higher cerebral blood oxygen level-dependent signals 
(BOLD) in specific primary and secondary motor areas were 
found during myotonia episodes. This was interpreted as a rela-
tionship between myotonia and high-order motor control areas 
(44). In another study, the severity of myotonia correlated with 
diffuse white matter alterations in specific primary and secondary 
motor areas (45). There are contradictory reports about the cor-
relation between myotonia, grip strength, and CTG-repeat length 
(46, 47) for DM1 patients. Overall, grip strength correlates 
negatively with CTG-repeat length in most studies, but this is 
not necessarily true for myotonia. In one recent study, there was 
a statistically significant correlation between grip myotonia and 
CTG-repeat length, but this was not clinically meaningful and 
not predictive (47).
Myotonia seems to be usually mild to moderate or even absent 
in many DM2 patients, impacting only minimally their quality 
of life (36). However, its occurrence in different cohorts ranges 
between 24 and 75% (30, 32, 40). This variability is partly due to 
the discrepancy sometimes observed between a history of myo-
tonia reported by patients and the clinical evidence of myotonic 
phenomenon, which is observed on neurological examination 
only in a minority of DM2 patients. Few patients may, however, 
display a severe myotonia and in some of these cases additional 
mutations in ion channel genes CLCN1 and SCN4A have been 
identified (48, 49). It is, therefore, advised to screen atypical cases 
with severe myotonia for mutation in these genes that act as phe-
notype modifier enhancing the myotonic phenomenon in DM2 
(49). Particularly limb girdle myotonia is frequently neglected 
and underdiagnosed. With aging, the presence of myotonia 
gradually becomes less clinically relevant as it is overwhelmed 
by the gradually worsening of muscle weakness (32). This trend 
is also confirmed in studies assessing quality of life of DM2 
patients, where significant predictors of worse QoL (quality of 
life) were older age, worse muscle strength, and higher level of 
fatigue (50).
Musculoskeletal Pain or Myalgia
Musculoskeletal pain or myalgia may be present in some DM1 
patients, but is less frequent in comparison to DM2 (Table  2). 
However, with the progression of the disease, a muscular imbal-
ance due to weakness may occur and secondary complications 
such as regional myofascial pain or joint pain syndromes may 
develop even in DM1. In DM2, about 60% of patients complain 
of diffuse myalgia. These are usually exercise-related and worsen 
in cold temperatures (33, 51). Some patients consider pain as the 
most disabling symptom of the disease also because of its poor 
response to common analgesics (7). The pathophysiological 
mechanism of myalgia in DM2 is yet to be elucidated, but it is 
probably related to specific molecular changes occurring in the 
muscles of DM2 patients (52).
For adult-onset DM1, the first muscular symptoms can become 
apparent in early adulthood, but some patients may exhibit 
subtle symptoms like grip myotonia, ptosis or slurred speech in 
childhood. Patients with classic DM1 are typically diagnosed at 
around 30 years, but mildly affected patients with CTG-length 
50–100 may present solely some slight myotonia or cataracts and 
may have their diagnosis delayed until they are around 40 years 
old (28). The clinical onset of DM2 typically occurs later than 
DM1, around the third to fourth decade; it may, however, often 
go unrecognized for several years due to only mild or unspecific 
clinical symptoms like myalgia or muscle cramps.
Muscular Respiratory Symptoms
Respiratory muscle weakness will occur in a high percentage of 
the patients with DM1 in an early stage of the disease and chronic 
respiratory failure may develop (53). Expiratory muscles seem to 
be affected sooner than inspiratory muscles, resulting in early 
recurrent pneumonia due to a weak cough and insufficient airway 
clearance. The exact prevalence of respiratory insufficiency in 
DM1 is unclear because symptoms of nocturnal hypoventilation 
overlap with typical neuropsychological symptoms like fatigue, 
daytime sleepiness, and concentration difficulties (54). As both 
respiratory muscle weakness and cardiac symptoms account 
most for the reduced survival of the patients, repeated testing for 
early diagnosis is essential. A pure respiratory muscle weakness 
rarely occurs in DM2 and only about 6–15% of patients require 
non-invasive ventilation (55).
eXTRAMUSCULAR SYMPTOMS
CNS Symptoms
Fatigue, daytime sleepiness, and concentration difficulties are 
frequently reported symptoms in DMs. In DM1, cognitive deficits 
were initially attributed to a low IQ or mental retardation, but 
recent studies show that this assumption was wrong for a large 
cohort of patients and mainly applies for cases of congenital myo-
tonic dystrophy (CDM). In fact, for the classic phenotype of DM1, 
neuropsychological deficits are as variable as muscular symptoms, 
and even recent publications about the correlation of CTG-repeat 
size and neuropsychological deficits show contradictory study 
results (56–58). There seems to be a correlation between diffuse 
brain alterations in primarily white and secondary gray matter, 
linking the DM1 to the group of brain disconnection disorders (59). 
Caso et al. investigated 51 DM1 patients and found a correlation 
between changes in brain white matter and cognitive impairment 
(60). Cerebral white matter hyperintensities have been observed 
in both DM1 and DM2 patients, especially in those older than 
40 years, but their clinical and functional significance still remains 
unclear (61–63). In a recent study about the educational profile of 
a large cohort of young DM1 patients, no significant differences 
compared to the healthy population were found (35), assuming 
that cognitive and concentration disturbances may occur later in 
the course of the disease in the context of a variable premature 
cognitive decline, as suggested by the study of Modoni et al. (56). 
Mild cognitive and behavioral symptoms are also present in 
DM2 patients. In particular, altered visuo-spatial and executive 
functions, reduced attention and flexibility of thinking, avoid-
ant behavioral trait, and depression have been detected in these 
patients (63, 64). In many cases, neuropsychological disturbances 
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jeopardize the ability to work and reduce the quality of life more 
than muscular symptoms.
Excessive daytime sleepiness, fatigue, and concentration dif-
ficulties may also be caused by central sleep disturbances or sleep 
apnea. Sleep-disordered breathing is one of the earliest manifes-
tations and occurs in a high percentage of patients with DM1 
(65), but overlapping symptoms of nocturnal hypoventilation 
and CNS symptoms may delay diagnosis and treatment. Chronic 
central sleep-disordered breathing has an impact on quality of 
life, morbidity, and mortality and should be assessed frequently 
in every patient with DM1 (54, 55, 66).
Until now, little is known about changes in CNS causing 
cognitive deficits and central sleep disrupted breathing. Almost 
every clinical study is conducted with the usually more affected 
DM1 patients, therefore data for DM2 patients are limited. On 
a molecular basis, MBNL1 and probably CELF may both be 
involved in CNS alterations, but little is known about molecular 
defects causing highly variable CNS symptoms in DM1 (42, 43). 
The above mentioned aspects lead to a discussion as to whether 
CNS dysfunction is caused by altered neurodevelopment, by 
neuro-dysfunction or by neurodegeneration within the definition 
of progeroid diseases (67). The hypothesis of a neurodegenerative 
disease is endorsed by findings of tau pathology and neurofibril-
lary degenerations, even if no correlations with CTG-repeat 
length were found (68). Overall, CNS dysfunction seems to be 
multifactorial.
eyes
The most frequent, early and typical extramuscular manifesta-
tion is the occurrence of early-onset cataract, observed in about 
50–60% of patients (30, 32, 69). A medical history of cataract sur-
gery in combination with muscular symptoms often leads to the 
diagnosis of DM, even in mildly affected patients without any sign 
of muscular impairment (70–72). The mechanisms underlying 
the pathophysiology of cataract in DMs are still largely unknown. 
At first, a potential effect of the CTG-mutation on the expression 
of neighboring genes such as SIX5 was considered in DM1 (73). 
But recent findings showed that SIX5 knock-out mice develop 
the nuclear type of cataract and not the posterior subcapsular/ 
cortical type that are commonly observed in DMs. In addition, 
SIX5 is not adjacent to the DM2 repeat expansion so that this 
mechanism could not explain cataracts in DM2. More recent 
studies of global transcription performed on samples of lens 
epithelium in patients affected by DM1, DM2, and controls, 
identi fied a high similarity as regards the pattern of gene expres-
sion between DM1 and DM2 and hypothesized that common 
molecular mechanisms should be involved in cataract formation 
probably involving interferon signaling pathways (74, 75).
endocrine Symptoms
Endocrine dysfunctions such as diabetes, hypogonadism, and secon-
dary hyperparathyroidism with decreased Vitamin-D levels are 
frequent in DMs and their occurrence increases with progression 
of the disease (76–78). A cross-sectional study on 68 DM1 patients 
showed at least one endocrine dysfunction in 44% at baseline 
and in 84% after 8 years (76). Diabetes mellitus, if not properly 
treated, may complicate and aggravate the clinical picture due 
to diabetic polyneuropathy with worsening of gait instability 
and distal weakness. Hyperparathyroidism may contribute 
to fatigue and muscle impairment (76). More rarely, abnormali-
ties in growth hormone secretion and glucose intolerance may 
be observed (79).
Hearing impairment
Some degree of hearing loss has been described in DM2 since its 
first description (80). A recent systematic study on 56 Dutch and 
French DM2 patients then demonstrated that a mild to moder-
ate hearing impairment was present in about 60% of examined 
patients. It is mostly a cochlear sensorineural hearing impairment 
which may be interpreted as an early presbycusis (81), well fitting 
in the interpretation of DMs as premature aging diseases. Similar 
features of cochlear impairment have also been described in some 
studies on DM1 patients (82).
Cardiac Symptoms
In DMs, cardiac involvement is common. Cardiologic comor-
bidities include arrhythmias, atrial fibrillation, and conduction 
defects (e.g., AV-blocks) and often requires the implantation of 
pacemakers. Other infrequent manifestations are sudden death, 
heart failure, Brugada syndrome, ischemic heart disease, and 
mitral valve prolapse (83, 84). Dilated cardiomyopathies may 
also occur in some patients, but are not frequently found. Cardiac 
abnormalities in DM2 are similar to those observed in DM1 
but occur less frequently. According to a recent observational 
case–control study on a large cohort of DM2/DM1 patients, it 
emerged that electrocardiographic abnormalities as PR > 200 ms 
and QRS > 100 ms were more frequent in DM1 (respectively, 31 
and 48%) than DM2 patients (10 and 17%). Of those, 6 DM2 vs. 28 
DM1 patients needed a pacemaker/implanted cardioverter (85). 
In the same study, echocardiography did not show any significant 
structural abnormalities but it was previously reported that a car-
diomyopathy might occur in about 3% of DM2 patients. In DM1, 
the severity of cardiac involvement seems directly related with the 
size of CTG-expansion as recently studied by Chong-Nguyen et al. 
(9, 30, 85, 86). Atrial fibrillations and arrhythmias increase the risk 
of cerebral ischemia (87) and mortality and morbidity significantly 
depend on early cardiologic diagnosis and treatment (83).
Gastrointestinal Symptoms
Along with elevations of creatine kinase, elevations of AST 
and ALT are frequent in patients with DM (88). In some cases, 
liver biopsies are performed because of these elevated “hepatic” 
enzymes without retrieving any pathologic result. The elevation 
of gamma-GT is suggested to be caused by contractions of bile 
canaliculi and bile ductules, whereas elevated levels of AST and 
ALT have their origin in skeletal muscle and go along with eleva-
tions of creatine kinase (89).
Alternating constipation, pseudo-constipation, bloating, and 
diarrhea are frequently reported symptoms in DM1, accompanied 
by stomach cramps, reflux, and regurgitation. They are caused 
by involvement of smooth and striated muscles and endocrine 
dysfunctions (90, 91). Swallowing problems are typical for DM1 
patients and due to reduced oral transport that is caused by 
myotonia and weakness of the tongue. Dysphagia is caused by 
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reduced swallowing reflex and reduced esophageal motility (92) 
which causes the major clinical problem by risk of aspiration. In 
conjunction with weakness of early affected expiratory muscles, 
this results in recurrent pneumonia and increased risk of death. 
A reduced or absent gastrointestinal peristaltic movement was 
earlier shown in radiological studies as well as delayed intestinal 
transits (93). Megacolon with the risk of ileus, volvulus and rup-
ture, is a significant and life-threatening complication. Delayed 
emptying of the gall bladder may increase the risk for gallstones.
Cancer
A higher incidence for neoplasms was found in several studies 
(28, 94, 95), most of them showed a predisposition in patients 
with DM1 for cancers such as skin cancer (like benign calcify-
ing cutaneous tumors, pilomatricomas), thyroid, testicular, and 
prostate cancer. Because of the limited number of high-quality 
surveys and studies about the prevalence of cancer in DM1, 
further research is needed. A survey from the UK DM registry 
showed that 12.4% of the DM1/DM2 patients reported at least 
one benign tumor and 6.2% reported at least one malignant 
tumor with a high incidence of skin tumors (96), but there was 
no epidemiologic correlation with a non-DM-population.
Peripheral Polyneuropathy
There is some debate as to whether peripheral neuropathy is a 
multisystemic manifestation of DMs or are caused by metabolic 
and endocrine dysfunctions. Its manifestation is not typical at 
early stages of the disease but may occur in about one-third of 
patients in later stages (97) of DM1 patients and contributes to 
balance impairment and increased risk of falls (31, 98). There 
were no significant correlations between age, duration of neuro-
muscular symptoms or CTG-repeat size (98, 99), suggesting that 
the affection of peripheral nerve system is secondary to metabolic 
and endocrine dysfunctions.
CONGeNiTAL MYOTONiC DYSTROPHY 
(CDM)
Patients with congenital DM1 have large CTG-expansions of 
more than 800, usually around 1,000. Characteristically, these 
large expansions are caused by maternal transmission, but 
CDM with paternal transmission is also known (23, 100–102). 
Clinically, CDM patients are severely affected and symptoms are 
often present before birth as polyhydramnios and reduced fetal 
movement. Hypotonia, generalized weakness, hyporeflexia, bilat-
eral talipes, contractures, arthrogryposis, facial dysmorphia (carp 
mouth, ptosis, long neck and face, temporal muscle atrophy), 
and a weak cry are typical symptoms at birth or in the first days 
after delivery. Weak sucking and respiratory insufficiency often 
make ventilatory support unavoidable. Respiratory insufficiency 
is present in about 50% of newborns and is the main cause of 
dramatically reduced survival with a mortality rate of 30–40% 
(103). Infants who survive will typically reach their motor and 
cognitive milestones with some delay but might be able to walk 
independently. Similarly to DM1, a distal weakness is typical in 
CDM and a proximal involvement indicates a poor prognosis 
(104). Besides muscular symptoms, cognitive impairment, and 
neuropsychological disorders are the most common and vari-
able manifestations in CDM. Symptoms range from intellectual 
impairment to selective cognitive impairment, apathy, and 
autism, as well as impaired attention, severe anxiety, and mood 
and depression syndromes (3, 102, 105–107). In the course of the 
disease, patients might require special schooling. In their third 
and fourth decades, patients may develop secondary complica-
tions, such as severe contractures, scoliosis, and worsening of 
cardiorespiratory symptoms (4).
CHiLDHOOD/JUveNiLe ONSeT DM1
The childhood and juvenile onset DM1 echoes the broad overlap-
ping spectrum of symptoms of the congenital and the adult pheno-
types. Commonly, there is an expansion of CTG-repeats of more 
than 800 repeats. First clinical symptoms may become apparent at 
age 1–10 for childhood onset and at age 10–20 for juvenile onset 
(3). Neurocognitive symptoms such as learning disability and 
learning difficulties are often prominent at age around 10 years 
and may become earlier apparent than muscular symptoms 
(107). In contrast to CDM, prenatal abnormalities or muscular 
symptoms right after delivery (neonatal hypotonia, sucking and 
swallowing difficulties and secondary dysmorphic features) are 
not typical, but a mild facial weakness or subtle facial dysmorphia 
may occur (3, 108). Early motor development is normal or only 
slightly delayed. Principal complaints in early childhood are 
speech and learning difficulties because of a mental handicap. At 
school, learning difficulties may become apparent and sometimes 
require special education. A study on 28 childhood-DM-patients 
showed that the full-scale IQ was significantly decreased (73.6) 
and 68% of the patients had repeated at least one school grade. 
54% had additional psychiatric symptoms such as anxiety disor-
der, mood disorder, and attention-deficit-hyperactivity disorder 
(107). In adolescence, patients may show typical muscular and 
non-muscular symptoms of adult-onset DM1, e.g., like distal 
weakness, clinical myotonia, or gastrointestinal symptoms. 
Cardiologic symptoms, such as cardiac arrhythmias or cardio-
myopathy, may occur, also leading to severe complications and 
sudden death (83). Life expectancy is not necessarily reduced, 
as long as core symptoms are recognized and treated sufficiently.
CONCLUSiON
Myotonic dystrophies represent the most variable clinical 
phenotypes, so treatment stratification is key for any modern 
therapeutic approach. We still need much more understanding 
of the signs and symptoms of DM patients in correlation to their 
molecular origins.
AUTHOR CONTRiBUTiONS
SW: review of publications, writing, critical revision of manuscript 
for intellectual content, and final approval of the manuscript. FM: 
review of publications, writing, and critical revision of manu-
script for intellectual content. BS: critical revision of manuscript 
for intellectual content.
7Wenninger et al. Clinical Phenotypes of Myotonic Dystrophies
Frontiers in Neurology | www.frontiersin.org May 2018 | Volume 9 | Article 303
ReFeReNCeS
1. Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, 
et  al. Population frequency of myotonic dystrophy: higher than expected 
frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur 
J Hum Genet (2011) 19(7):776–82. doi:10.1038/ejhg.2011.23 
2. Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, et al. Myotonic 
dystrophy type 2 (DM2) and related disorders report of the 180th ENMC 
workshop including guidelines on diagnostics and management 3-5 
December 2010, Naarden, The Netherlands. Neuromuscul Disord (2011) 
21(6):443–50. doi:10.1016/j.nmd.2011.03.013 
3. Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dys-
trophy: current aspects of disease and future directions. World J Clin Pediatr 
(2015) 4(4):66–80. doi:10.5409/wjcp.v4.i4.66 
4. Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, 
genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 
(2015) 1852(4):594–606. doi:10.1016/j.bbadis.2014.05.019 
5. Medica I, Markovic D, Peterlin B. Genetic epidemiology of myotonic dys-
trophy in Istria, Croatia. Acta Neurol Scand (1997) 95(3):164–6. doi:10.1111/ 
j.1600-0404.1997.tb00089.x 
6. Vohanka S, Parmova O, Mazanec R, Strenkova J, Ridzon P, Ehler E, et  al. 
Myotonic dystrophy in Czech Republic: data from the national registry. 
J Neurol Sci (2015) 357:e347–8. doi:10.1016/j.jns.2015.08.1232 
7. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, et al. 140th 
ENMC International Workshop: myotonic dystrophy DM2/PROMM and 
other myotonic dystrophies with guidelines on management. Neuromuscul 
Disord (2006) 16(6):403–13. doi:10.1016/j.nmd.2006.03.010 
8. Suominen S, Koskenvuo K, Sillanmaki L, Vahtera J, Korkeila K, Kivimaki M, 
et al. Non-response in a nationwide follow-up postal survey in Finland: a 
register-based mortality analysis of respondents and non-respondents of the 
Health and Social Support (HeSSup) Study. BMJ Open (2012) 2(2):e000657. 
doi:10.1136/bmjopen-2011-000657 
9. Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Durre J, Bultmann B, 
et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology (2004) 
63(12):2402–4. doi:10.1212/01.WNL.0000147335.10783.E4 
10. Segel R, Silverstein S, Lerer I, Kahana E, Meir R, Sagi M, et al. Prevalence of 
myotonic dystrophy in Israeli Jewish communities: inter-community varia-
tion and founder premutations. Am J Med Genet A (2003) 119A(3):273–8. 
doi:10.1002/ajmg.a.20177 
11. Pinessi L, Bergamini L, Cantello R, Di Tizio C. Myotonia congenita and 
myotonic dystrophy: descriptive epidemiological investigation in Turin, Italy 
(1955-1979). Ital J Neurol Sci (1982) 3(3):207–10. doi:10.1007/BF02043311 
12. Siciliano G, Manca M, Gennarelli M, Angelini C, Rocchi A, Iudice A, et al. 
Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diag-
nosis. Clin Genet (2001) 59(5):344–9. doi:10.1034/j.1399-0004.2001.590508.x 
13. Vanacore N, Rastelli E, Antonini G, Bianchi ML, Botta A, Bucci E, et al. An 
age-standardized prevalence estimate and a sex and age distribution of myo-
tonic dystrophy types 1 and 2 in the Rome province, Italy. Neuroepidemiology 
(2016) 46(3):191–7. doi:10.1159/000444018 
14. Nakagawa M, Nakahara K, Yoshidome H, Suehara M, Higuchi I, Fujiyama J, 
et al. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. 
Classification with molecular biological techniques. Neuroepidemiology (1991) 
10(4):185–91. doi:10.1159/000110268 
15. Burcet J, Canellas F, Cavaller G, Vich M. [Epidemiologic study of myotonic 
dystrophy on the island of Mallorca]. Neurologia (1992) 7(2):61–4. 
16. Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New 
Zealand. N Z Med J (2006) 119(1241):U2145. 
17. Magee A, Nevin NC. The epidemiology of myotonic dystrophy in Northern 
Ireland. Community Genet (1999) 2(4):179–83. doi:10.1159/000016209 
18. Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited 
neuromuscular disease in Northern Ireland. Neuromuscul Disord (1996) 
6(1):69–73. doi:10.1016/0960-8966(94)00017-4 
19. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. 
Prevalence of genetic muscle disease in Northern England: in-depth analysis 
of a muscle clinic population. Brain (2009) 132(Pt 11):3175–86. doi:10.1093/
brain/awp236 
20. Bouchard G, Roy R, Declos M, Mathieu J, Kouladjian K. Origin and diffu-
sion of the myotonic dystrophy gene in the Saguenay region (Quebec). Can 
J Neurol Sci (1989) 16(1):119–22. doi:10.1017/S0317167100028651 
21. Mladenovic J, Pekmezovic T, Todorovic S, Rakocevic-Stojanovic V, Savic D, 
Romac S, et  al. Epidemiology of myotonic dystrophy type 1 (Steinert 
disease) in Belgrade (Serbia). Clin Neurol Neurosurg (2006) 108(8):757–60. 
doi:10.1016/j.clineuro.2006.04.004 
22. Hsiao KM, Chen SS, Li SY, Chiang SY, Lin HM, Pan H, et al. Epidemiological 
and genetic studies of myotonic dystrophy type 1 in Taiwan. Neuroepide mio­
logy (2003) 22(5):283–9. doi:10.1159/000071191 
23. Brunner HG, Bruggenwirth HT, Nillesen W, Jansen G, Hamel BC, Hoppe RL, 
et al. Influence of sex of the transmitting parent as well as of parental allele 
size on the CTG expansion in myotonic dystrophy (DM). Am J Hum Genet 
(1993) 53(5):1016–23. 
24. Bouchard JP, Cossette L, Bassez G, Puymirat J. Natural history of skeletal 
muscle involvement in myotonic dystrophy type 1: a retrospective study in 
204 cases. J Neurol (2015) 262(2):285–93. doi:10.1007/s00415-014-7570-x 
25. Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management 
and new therapies. Curr Opin Neurol (2014) 27(5):599–606. doi:10.1097/
WCO.0000000000000128 
26. De Antonio M, Dogan C, Hamroun D, Mati M, Zerrouki S, Eymard B, et al. 
Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic 
registry-based study with implications for disease classification. Rev Neurol 
(2016) 172(10):572–80. doi:10.1016/j.neurol.2016.08.003 
27. Mateos-Aierdi AJ, Goicoechea M, Aiastui A, Fernandez-Torron R, Garcia-
Puga M, Matheu A, et  al. Muscle wasting in myotonic dystrophies: a 
model of premature aging. Front Aging Neurosci (2015) 7:125. doi:10.3389/
fnagi.2015.00125 
28. Bird TD. Myotonic dystrophy type 1. In: Adam MP, Ardinger HH, Pagon 
RA, Wallace SE, Bean LJH, Stephens K et al. editors. GeneReviews® [Internet]. 
Seattle, WA: University of Washington 1993–2018.
29. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. 
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. 
Science (2001) 293(5531):864–7. doi:10.1126/science.1062125 
30. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et  al. 
Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. 
Neurology (2003) 60(4):657–64. doi:10.1212/01.WNL.0000054481.84978.F9 
31. Jiménez-Moreno AC, Raaphorst J, Babačić H, Wood L, van Engelen B, 
Lochmüller H, et  al. Falls and resulting fractures in myotonic dystrophy: 
results from a multinational retrospective survey. Neuromuscul Disord (2018) 
28(3):229–35. doi:10.1016/j.nmd.2017.12.010 
32. Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B. Assessing the 
influence of age and gender on the phenotype of myotonic dystrophy type 2. 
J Neurol (2017) 264(12):2472–80. doi:10.1007/s00415-017-8653-2 
33. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, et al. 
Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle 
weakness, and cataracts. Neurology (1994) 44(8):1448–52. doi:10.1212/WNL. 
44.8.1448 
34. Kornblum C, Lutterbey G, Bogdanow M, Kesper K, Schild H, Schroder R, 
et  al. Distinct neuromuscular phenotypes in myotonic dystrophy types 1 
and 2: a whole body highfield MRI study. J Neurol (2006) 253(6):753–61. 
doi:10.1007/s00415-006-0111-5 
35. Stahl K, Wenninger S, Schuller A, Montagnese F, Schoser B. [Educational 
and professional qualifications of adults with myotonic dystrophies – a mis-
leading perception by the myopathic face?]. Fortschr Neurol Psychiatr (2016) 
84(4):211–6. doi:10.1055/s-0042-104193 
36. Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, et  al. 
Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). 
Neurology (2015) 85(24):2136–46. doi:10.1212/WNL.0000000000002225 
37. de Swart BJ, van Engelen BG, van de Kerkhof JP, Maassen BA. Myotonia and 
flaccid dysarthria in patients with adult onset myotonic dystrophy. J Neurol 
Neurosurg Psychiatry (2004) 75(10):1480–2. doi:10.1136/jnnp.2003.032151 
38. Logigian EL, Blood CL, Dilek N, Martens WB, Moxley RT, Wiegner AW, et al. 
Quantitative analysis of the “warm-up” phenomenon in myotonic dystrophy 
type 1. Muscle Nerve (2005) 32(1):35–42. doi:10.1002/mus.20339 
39. Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle sodium and chloride 
channel diseases. Brain (1995) 118(Pt 2):547–63. doi:10.1093/brain/118.2.547 
40. Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and 
minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 
(2010) 41(6):758–62. doi:10.1002/mus.21615 
41. Meola G. Clinical aspects, molecular pathomechanisms and management 
of myotonic dystrophies. Acta Myol (2013) 32(3):154–65. 
8Wenninger et al. Clinical Phenotypes of Myotonic Dystrophies
Frontiers in Neurology | www.frontiersin.org May 2018 | Volume 9 | Article 303
42. Caillet-Boudin ML, Fernandez-Gomez FJ, Tran H, Dhaenens CM, Buee L, 
Sergeant N. Brain pathology in myotonic dystrophy: when tauopathy meets 
spliceopathy and RNAopathy. Front Mol Neurosci (2014) 6:57. doi:10.3389/
fnmol.2013.00057 
43. Goodwin M, Mohan A, Batra R, Lee KY, Charizanis K, Fernandez Gomez FJ, 
et  al. MBNL sequestration by toxic RNAs and RNA misprocessing in the 
myotonic dystrophy brain. Cell Rep (2015) 12(7):1159–68. doi:10.1016/j.
celrep.2015.07.029 
44. Toth A, Lovadi E, Komoly S, Schwarcz A, Orsi G, Perlaki G, et al. Cortical 
involvement during myotonia in myotonic dystrophy: an fMRI study. Acta 
Neurol Scand (2015) 132(1):65–72. doi:10.1111/ane.12360 
45. Zanigni S, Evangelisti S, Giannoccaro MP, Oppi F, Poda R, Giorgio A, et al. 
Relationship of white and gray matter abnormalities to clinical and genetic 
features in myotonic dystrophy type 1. Neuroimage Clin (2016) 11:678–85. 
doi:10.1016/j.nicl.2016.04.012 
46. Andersen G, Orngreen MC, Preisler N, Colding-Jorgensen E, Clausen T, 
Duno M, et al. Muscle phenotype in patients with myotonic dystrophy type 
1. Muscle Nerve (2013) 47(3):409–15. doi:10.1002/mus.23535 
47. Hogrel JY, Ollivier G, Ledoux I, Hebert LJ, Eymard B, Puymirat J, et  al. 
Relationships between grip strength, myotonia, and CTG expansion in 
myotonic dystrophy type 1. Ann Clin Transl Neurol (2017) 4(12):921–5. 
doi:10.1002/acn3.496 
48. Cardani R, Giagnacovo M, Botta A, Rinaldi F, Morgante A, Udd B, et  al. 
Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset 
of myotonic dystrophy type 2. J Neurol (2012) 259(10):2090–9. doi:10.1007/
s00415-012-6462-1 
49. Bugiardini E, Rivolta I, Binda A, Soriano Caminero A, Cirillo F, Cinti A, 
et  al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 
phenotype. Neuromuscul Disord (2015) 25(4):301–7. doi:10.1016/j.nmd. 
2015.01.006 
50. Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M, et al. 
Quality of life in patients with myotonic dystrophy type 2. J Neurol Sci (2016) 
365:158–61. doi:10.1016/j.jns.2016.04.018 
51. Suokas KI, Haanpaa M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients 
with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 
(2012) 45(1):70–4. doi:10.1002/mus.22249 
52. Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S. 
A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine 
(2016) 7:205–11. doi:10.1016/j.ebiom.2016.03.017 
53. Reardon W, Newcombe R, Fenton I, Sibert J, Harper PS. The natural history 
of congenital myotonic dystrophy: mortality and long term clinical aspects. 
Arch Dis Child (1993) 68(2):177–81. doi:10.1136/adc.68.2.177 
54. Boentert M, Wenninger S, Sansone VA. Respiratory involvement in neuro-
muscular disorders. Curr Opin Neurol (2017) 30(5):529–37. doi:10.1097/
WCO.0000000000000470 
55. Sansone VA, Gagnon C. 207th ENMC Workshop on chronic respiratory 
insufficiency in myotonic dystrophies: management and implications for 
research, 27-29 June 2014, Naarden, The Netherlands. Neuromuscul Disord 
(2015) 25(5):432–42. doi:10.1016/j.nmd.2015.01.011 
56. Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. 
Characterization of the pattern of cognitive impairment in myotonic 
dystrophy type 1. Arch Neurol (2004) 61(12):1943–7. doi:10.1001/
archneur.61.12.1943 
57. Winblad S, Lindberg C, Hansen S. Cognitive deficits and CTG repeat expan-
sion size in classical myotonic dystrophy type 1 (DM1). Behav Brain Funct 
(2006) 2:16. doi:10.1186/1744-9081-2-16 
58. Sugiyama A, Sone D, Sato N, Kimura Y, Ota M, Maikusa N, et al. Brain gray 
matter structural network in myotonic dystrophy type 1. PLoS One (2017) 
12(11):e0187343. doi:10.1371/journal.pone.0187343 
59. Minnerop M, Weber B, Schoene-Bake JC, Roeske S, Mirbach S, Anspach C, 
et al. The brain in myotonic dystrophy 1 and 2: evidence for a predominant 
white matter disease. Brain (2011) 134(Pt 12):3530–46. doi:10.1093/brain/
awr299 
60. Caso F, Agosta F, Peric S, Rakocevic-Stojanovic V, Copetti M, Kostic VS, 
et al. Cognitive impairment in myotonic dystrophy type 1 is associated with 
white matter damage. PLoS One (2014) 9(8):e104697. doi:10.1371/journal.
pone.0104697 
61. Kornblum C, Reul J, Kress W, Grothe C, Amanatidis N, Klockgether T, 
et al. Cranial magnetic resonance imaging in genetically proven myotonic 
dystrophy type 1 and 2. J Neurol (2004) 251(6):710–4. doi:10.1007/s00415- 
004-0408-1 
62. Franc DT, Muetzel RL, Robinson PR, Rodriguez CP, Dalton JC, Naughton CE, 
et al. Cerebral and muscle MRI abnormalities in myotonic dystrophy. Neuro­
muscul Disord (2012) 22(6):483–91. doi:10.1016/j.nmd.2012.01.003 
63. Schneider-Gold C, Bellenberg B, Prehn C, Krogias C, Schneider R, Klein J, 
et al. Cortical and subcortical grey and white matter atrophy in myotonic 
dystrophies type 1 and 2 is associated with cognitive impairment, depression 
and daytime sleepiness. PLoS One (2015) 10(6):e0130352. doi:10.1371/
journal.pone.0130352 
64. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et  al. 
Executive dysfunction and avoidant personality trait in myotonic dystrophy 
type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). 
Neuromuscul Disord (2003) 13(10):813–21. doi:10.1016/S0960-8966(03) 
00137-8 
65. Bianchi ML, Losurdo A, Di Blasi C, Santoro M, Masciullo M, Conte G, et al. 
Prevalence and clinical correlates of sleep disordered breathing in myotonic 
dystrophy types 1 and 2. Sleep Breath (2014) 18(3):579–89. doi:10.1007/
s11325-013-0921-5 
66. Ho G, Widger J, Cardamone M, Farrar MA. Quality of life and excessive 
daytime sleepiness in children and adolescents with myotonic dystrophy type 
1. Sleep Med (2017) 32:92–6. doi:10.1016/j.sleep.2016.12.005 
67. Gourdon G, Meola G. Myotonic dystrophies: state of the art of new therapeu-
tic developments for the CNS. Front Cell Neurosci (2017) 11:101. doi:10.3389/
fncel.2017.00101 
68. Itoh K, Mitani M, Kawamoto K, Futamura N, Funakawa I, Jinnai K, et al. 
Neuropathology does not correlate with regional differences in the extent of 
expansion of CTG repeats in the brain with myotonic dystrophy type 1. Acta 
Histochem Cytochem (2010) 43(6):149–56. doi:10.1267/ahc.10019 
69. Ekstrom AB, Tulinius M, Sjostrom A, Aring E. Visual function in con-
genital and childhood myotonic dystrophy type 1. Ophthalmology (2010) 
117(5):976–82. doi:10.1016/j.ophtha.2010.01.055 
70. Brunner HG, Nillesen W, van Oost BA, Jansen G, Wieringa B, Ropers HH, 
et al. Presymptomatic diagnosis of myotonic dystrophy. J Med Genet (1992) 
29(11):780–4. doi:10.1136/jmg.29.11.780 
71. Kidd A, Turnpenny P, Kelly K, Clark C, Church W, Hutchinson C, et  al. 
Ascertainment of myotonic dystrophy through cataract by selective screen-
ing. J Med Genet (1995) 32(7):519–23. doi:10.1136/jmg.32.7.519 
72. Rakocevic-Stojanovic V, Peric S, Pesovic J, Sencanic I, Bozic M, Svikovic S, 
et  al. Genetic testing of individuals with pre-senile cataract identifies 
patients with myotonic dystrophy type 2. Eur J Neurol (2017) 24(11):e79–80. 
doi:10.1111/ene.13401 
73. Sato S, Nakamura M, Cho DH, Tapscott SJ, Ozaki H, Kawakami K. 
Identification of transcriptional targets for Six5: implication for the patho-
genesis of myotonic dystrophy type 1. Hum Mol Genet (2002) 11(9):1045–58. 
doi:10.1093/hmg/11.9.1045 
74. Rhodes JD, Lott MC, Russell SL, Moulton V, Sanderson J, Wormstone IM, 
et  al. Activation of the innate immune response and interferon signalling 
in myotonic dystrophy type 1 and type 2 cataracts. Hum Mol Genet (2012) 
21(4):852–62. doi:10.1093/hmg/ddr515 
75. Shao D, Zhu X, Sun W, Huo L, Chen W, Wang H, et  al. Investigation of 
the molecular mechanisms underlying myotonic dystrophy types 1 and 
2 cataracts using microRNAtarget gene networks. Mol Med Rep (2017) 
16(4):3737–44. doi:10.3892/mmr.2017.7059 
76. Passeri E, Bugiardini E, Sansone VA, Valaperta R, Costa E, Ambrosi B, et al. 
Vitamin D, parathyroid hormone and muscle impairment in myotonic dys-
trophies. J Neurol Sci (2013) 331(1–2):132–5. doi:10.1016/j.jns.2013.06.008 
77. Terracciano C, Rastelli E, Morello M, Celi M, Bucci E, Antonini G, et  al. 
Vitamin D deficiency in myotonic dystrophy type 1. J Neurol (2013) 260(9): 
2330–4. doi:10.1007/s00415-013-6984-1 
78. Dahlqvist JR, Orngreen MC, Witting N, Vissing J. Endocrine function 
over time in patients with myotonic dystrophy type 1. Eur J Neurol (2015) 
22(1):116–22. doi:10.1111/ene.12542 
79. Matsumura T, Iwahashi H, Funahashi T, Takahashi MP, Saito T, Yasui K, 
et al. A cross-sectional study for glucose intolerance of myotonic dystrophy. 
J Neurol Sci (2009) 276(1–2):60–5. doi:10.1016/j.jns.2008.08.037 
80. Thornton CA, Griggs RC, Moxley RT III. Myotonic dystrophy with no tri-
nucleotide repeat expansion. Ann Neurol (1994) 35(3):269–72. doi:10.1002/
ana.410350305 
9Wenninger et al. Clinical Phenotypes of Myotonic Dystrophies
Frontiers in Neurology | www.frontiersin.org May 2018 | Volume 9 | Article 303
81. van Vliet J, Tieleman AA, van Engelen BGM, Bassez G, Servais L, Behin A, 
et al. Hearing impairment in patients with myotonic dystrophy type 2. 
Neurology (2018) 90(7):e615–22. doi:10.1212/WNL.0000000000004963 
82. Pisani V, Tirabasso A, Mazzone S, Terracciano C, Botta A, Novelli G, et al. 
Early subclinical cochlear dysfunction in myotonic dystrophy type 1. Eur 
J Neurol (2011) 18(12):1412–6. doi:10.1111/j.1468-1331.2011.03470.x 
83. Bassez G, Lazarus A, Desguerre I, Varin J, Laforet P, Becane HM, et  al. 
Severe cardiac arrhythmias in young patients with myotonic dystrophy 
type 1. Neurology (2004) 63(10):1939–41. doi:10.1212/01.WNL.0000144343. 
91136.CF 
84. Wahbi K, Algalarrondo V, Becane HM, Fressart V, Beldjord C, Azibi K, 
et  al. Brugada syndrome and abnormal splicing of SCN5A in myotonic 
dystrophy type 1. Arch Cardiovasc Dis (2013) 106(12):635–43. doi:10.1016/j.
acvd.2013.08.003 
85. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. 
The frequency and severity of cardiac involvement in myotonic dystrophy 
type 2 (DM2): long-term outcomes. Int J Cardiol (2013) 168(2):1147–53. 
doi:10.1016/j.ijcard.2012.11.076 
86. Chong-Nguyen C, Wahbi K, Algalarrondo V, Becane HM, Radvanyi-Hoffman H, 
Arnaud P, et al. Association between mutation size and cardiac involvement in 
myotonic dystrophy type 1: an analysis of the DM1-Heart Registry. Circ Cardio­
vasc Genet (2017) 10(3):e001526. doi:10.1161/CIRCGENETICS.116.001526 
87. Yoshida K, Aburakawa Y, Suzuki Y, Kuroda K, Kimura T. The frequency and 
risk factors for ischemic stroke in myotonic dystrophy type 1 patients. J Stroke 
Cerebrovasc Dis (2018) 27(4):914–8. doi:10.1016/j.jstrokecerebrovasdis.2017. 
10.030 
88. Ronnemaa T, Alaranta H, Viikari J, Tilvis R, Falck B. Increased activity of 
serum gamma-glutamyltransferase in myotonic dystrophy. Acta Med Scand 
(1987) 222(3):267–73. doi:10.1111/j.0954-6820.1987.tb10669.x 
89. Kalafateli M, Triantos C, Tsamandas A, Kounadis G, Labropoulou-Karatza C. 
Abnormal liver function tests in a patient with myotonic dystrophy type 1. 
Ann Hepatol (2012) 11(1):130–3. 
90. Brunner HG, Hamel BC, Rieu P, Howeler CJ, Peters FT. Intestinal pseudo- 
obstruction in myotonic dystrophy. J Med Genet (1992) 29(11):791–3. 
doi:10.1136/jmg.29.11.791 
91. Bellini M, Biagi S, Stasi C, Costa F, Mumolo MG, Ricchiuti A, et  al. 
Gastrointestinal manifestations in myotonic muscular dystrophy. World 
J Gastro enterol (2006) 12(12):1821–8. doi:10.3748/wjg.v12.i12.1821 
92. Ercolin B, Sassi FC, Mangilli LD, Mendonca LI, Limongi SC, de Andrade CR. 
Oral motor movements and swallowing in patients with myotonic dystrophy 
type 1. Dysphagia (2013) 28(3):446–54. doi:10.1007/s00455-013-9458-9 
93. Goldberg HI, Sheft DJ. Esophageal and colon changes in myotonia dystro-
phica. Gastroenterology (1972) 63(1):134–9. 
94. Gadalla SM, Lund M, Pfeiffer RM, Gortz S, Mueller CM, Moxley RT III, 
et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 
(2011) 306(22):2480–6. doi:10.1001/jama.2011.1796 
95. Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM. Increased cancer 
risks in myotonic dystrophy. Mayo Clin Proc (2012) 87(2):130–5. doi:10.1016/ 
j.mayocp.2011.09.005 
96. Alsaggaf R, Wang Y, Marini-Bettolo C, Wood L, Nikolenko N, Lochmuller H, 
et al. Benign and malignant tumors in the UK myotonic dystrophy patient 
registry. Muscle Nerve (2018) 57(2):316–20. doi:10.1002/mus.25736 
97. Peric S, Stojanovic VR, Nikolic A, Kacar A, Basta I, Pavlovic S, et al. Peripheral 
neuropathy in patients with myotonic dystrophy type 1. Neurol Res (2013) 
35(4):331–5. doi:10.1179/1743132812Y.0000000144 
98. Hermans MC, Faber CG, Vanhoutte EK, Bakkers M, De Baets MH, de 
Die-Smulders CE, et al. Peripheral neuropathy in myotonic dystrophy type 1. 
J Peripher Nerv Syst (2011) 16(1):24–9. doi:10.1111/j.1529-8027.2011. 
00313.x 
99. Bae JS, Kim OK, Kim SJ, Kim BJ. Abnormalities of nerve conduction 
studies in myotonic dystrophy type 1: primary involvement of nerves or 
incidental coexistence? J Clin Neurosci (2008) 15(10):1120–4. doi:10.1016/j.
jocn.2007.11.002 
100. Harper PS, Dyken PR. Early-onset dystrophia myotonica. Evidence support-
ing a maternal environmental factor. Lancet (1972) 2(7767):53–5. doi:10.1016/ 
S0140-6736(72)91548-6 
101. Zeesman S, Carson N, Whelan DT. Paternal transmission of the congenital 
form of myotonic dystrophy type 1: a new case and review of the literature. 
Am J Med Genet (2002) 107(3):222–6. doi:10.1002/ajmg.10141 
102. Angeard N, Gargiulo M, Jacquette A, Radvanyi H, Eymard B, Heron D. 
Cognitive profile in childhood myotonic dystrophy type 1: is there a global 
impairment? Neuromuscul Disord (2007) 17(6):451–8. doi:10.1016/j.nmd. 
2007.02.012 
103. Wallgren-Pettersson C, Bushby K, Mellies U, Simonds A. 117th ENMC 
workshop: ventilatory support in congenital neuromuscular disorders – 
congenital myopathies, congenital muscular dystrophies, congenital 
myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Nether-
lands. Neuromuscul Disord (2004) 14(1):56–69. doi:10.1016/j.nmd.2003. 
09.003 
104. Mathieu J, Allard P, Potvin L, Prevost C, Begin P. A 10-year study of mor-
tality in a cohort of patients with myotonic dystrophy. Neurology (1999) 
52(8):1658–62. doi:10.1212/WNL.52.8.1658 
105. Ekstrom AB, Hakenas-Plate L, Samuelsson L, Tulinius M, Wentz E. Autism 
spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals 
with congenital and childhood forms. Am J Med Genet B Neuropsychiatr 
Genet (2008) 147B(6):918–26. doi:10.1002/ajmg.b.30698 
106. Douniol M, Jacquette A, Guile JM, Tanguy ML, Angeard N, Heron D, 
et al. Psychiatric and cognitive phenotype in children and adolescents with 
myotonic dystrophy. Eur Child Adolesc Psychiatry (2009) 18(12):705–15. 
doi:10.1007/s00787-009-0037-4 
107. Douniol M, Jacquette A, Cohen D, Bodeau N, Rachidi L, Angeard N, 
et al. Psychiatric and cognitive phenotype of childhood myotonic dystrophy 
type 1. Dev Med Child Neurol (2012) 54(10):905–11. doi:10.1111/j.1469- 
8749.2012.04379.x 
108. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on 
current aspects. Semin Pediatr Neurol (2006) 13(2):71–9. doi:10.1016/j.
spen.2006.06.002 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Wenninger, Montagnese and Schoser. This is an open­access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
